Larazotide eased symptoms in phase II celiac trial

CHICAGO – Larazotide acetate, a first-in-class oral medication developed specifically to treat celiac disease, reduced both gastrointestinal and non-GI symptoms in patients who were symptomatic...

Field of Interest: Gastroentero...
Type: News Item

GERD may boost risk of MI

CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease. In a nationwide case-control study of prodigious proportions,...

Field of Interest: Gastroentero...
Type: News Item

GERD may boost risk of MI

CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease. In a nationwide case-control study of prodigious proportions,...

Field of Interest: Cardiology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness